Chimeric Antigen Receptor T Cell therapy

Reprograming our T cell product candidates

An emergence of a new treatment

For many years, the cornerstones of cancer treatment have been surgery, chemotherapy and radiation therapy.

Recent years have seen the emergence of cancer immunotherapy, in which treatments harness the power of a patient’s immune system to combat their disease.

T cells are a type of white blood cell that form part of the immune system’s natural protection against cancer and infection. Normally our T cells can detect and eliminate abnormal or cancerous cells but sometimes these cells can escape detection and develop into tumours.

To overcome this problem Autolus is applying its advanced cell programing technologies and specialized manufacturing processes to develop programmed T cell product candidates.

Latest Abstracts & Publications

See all
December 12 2022

Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL (AUTO1/22)

December 11 2022

Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (B-ALL) and Other B-Cell Malignancies

American Society of Hematology Annual Meeting
December 13 2021

Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)